About Pulse Biosciences (NASDAQ:PLSE)
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Symbol: NASDAQ:PLSE
- CUSIP: N/A
- Web: www.pulsebiosciences.com
- Market Cap: $337.85 million
- Outstanding Shares: 14,334,000
- 50 Day Moving Avg: $18.62
- 200 Day Moving Avg: $24.70
- 52 Week Range: $5.20 - $39.50
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.69 per share
- Price / Book: 13.94
- EBITDA: ($14,340,000.00)
- Return on Equity: -57.16%
- Return on Assets: -53.58%
- Current Ratio: 8.18%
- Quick Ratio: 8.18%
- Average Volume: 297,117 shs.
- Beta: 3.24
- Short Ratio: 7.67
Frequently Asked Questions for Pulse Biosciences (NASDAQ:PLSE)
What is Pulse Biosciences' stock symbol?
Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."
How were Pulse Biosciences' earnings last quarter?
When will Pulse Biosciences make its next earnings announcement?
Who are some of Pulse Biosciences' key competitors?
Some companies that are related to Pulse Biosciences include Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), ViewRay (VRAY), Accuray Incorporated (ARAY), Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Harvard Bioscience (HBIO), Neovasc (NVCN), IRIDEX Corporation (IRIX), Viveve Medical (VIVE), Edap Tms S.A. (EDAP), Presbia PLC (LENS), Fulgent Genetic (FLGT), Electromed (ELMD), Biolase (BIOL), Invivo Therapeutics Holdings Corp (NVIV) and Digirad Corporation (DRAD).
When did Pulse Biosciences IPO?
(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.
Who owns Pulse Biosciences stock?
Pulse Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include
DUGGAN ROBERT W
DUGGAN ROBERT W
DUGGAN ROBERT W
(23.90%). Company insiders that own Pulse Biosciences stock include Maky Zanganeh, Mitchell E Levinson, Robert J Greenberg, Robert W Duggan and Thierry B Thaure. View Institutional Ownership Trends for Pulse Biosciences.
How do I buy Pulse Biosciences stock?
Shares of Pulse Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pulse Biosciences' stock price today?
MarketBeat Community Rating for Pulse Biosciences (NASDAQ PLSE)MarketBeat's community ratings are surveys of what our community members think about Pulse Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Pulse Biosciences stock can currently be purchased for approximately $23.56.
Consensus Ratings for Pulse Biosciences (NASDAQ:PLSE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Pulse Biosciences (NASDAQ:PLSE)
Analysts' Ratings History for Pulse Biosciences (NASDAQ:PLSE)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Pulse Biosciences (NASDAQ:PLSE)Earnings History by Quarter for Pulse Biosciences (NASDAQ PLSE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Pulse Biosciences (NASDAQ:PLSE)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Pulse Biosciences (NASDAQ:PLSE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Pulse Biosciences (NASDAQ:PLSE)
Insider Ownership Percentage: 6.70%Insider Trades by Quarter for Pulse Biosciences (NASDAQ:PLSE)
Institutional Ownership Percentage: 9.55%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/24/2017||Robert W Duggan||Major Shareholder||Buy||2,000,000||$15.02||$30,040,000.00|| |
|9/18/2017||Maky Zanganeh||Director||Buy||29,775||$13.36||$397,794.00|| |
|9/18/2017||Robert W Duggan||Major Shareholder||Buy||409,918||$14.36||$5,886,422.48|| |
|9/14/2017||Mitchell E Levinson||Director||Buy||3,835||$12.30||$47,170.50|| |
|8/3/2017||Maky Zanganeh||Director||Buy||28,790||$23.96||$689,808.40|| |
|8/3/2017||Robert W Duggan||Major Shareholder||Buy||277,450||$23.14||$6,420,193.00|| |
|8/2/2017||Maky Zanganeh||Director||Buy||8,290||$25.15||$208,493.50|| |
|5/23/2017||Robert W Duggan||Major Shareholder||Buy||83,928||$26.86||$2,254,306.08|| |
|5/22/2017||Robert W Duggan||Major Shareholder||Buy||34,728||$26.25||$911,610.00|| |
|5/12/2017||Thierry B Thaure||Director||Sell||10,000||$24.40||$244,000.00|| |
|5/11/2017||Robert W Duggan||Major Shareholder||Buy||43,389||$21.04||$912,904.56|| |
|5/10/2017||Robert J Greenberg||Director||Sell||25,000||$21.12||$528,000.00|| |
|5/8/2017||Thierry B Thaure||Director||Sell||15,000||$22.49||$337,350.00|| |
|4/28/2017||Robert W Duggan||Major Shareholder||Buy||84,348||$23.88||$2,014,230.24|| |
|4/27/2017||Robert W Duggan||Major Shareholder||Buy||35,387||$24.79||$877,243.73|| |
|4/19/2017||Robert W Duggan||Major Shareholder||Buy||150,123||$23.77||$3,568,423.71|| |
|4/18/2017||Robert W Duggan||Major Shareholder||Buy||61,819||$25.49||$1,575,766.31|| |
|4/17/2017||Robert W Duggan||Major Shareholder||Buy||107,300||$24.81||$2,662,113.00|| |
|4/10/2017||Robert W. Duggan||Major Shareholder||Buy||191,464||$19.75||$3,781,414.00|| |
|3/20/2017||Maky Zanganeh||Director||Buy||18,240||$23.34||$425,721.60|| |
|3/18/2017||Robert W Duggan||Major Shareholder||Buy||205,127||$23.56||$4,832,792.12|| |
Headline Trends for Pulse Biosciences (NASDAQ:PLSE)
Latest Headlines for Pulse Biosciences (NASDAQ:PLSE)
Loading headlines, please wait.
Pulse Biosciences (PLSE) Chart for Sunday, October, 22, 2017